| 抗肿瘤血管生成靶向药物不良反应机制与处理进展 |
| |
| 引用本文： | 邵建芳,董斌,张庆华. 抗肿瘤血管生成靶向药物不良反应机制与处理进展[J]. 中国综合临床, 2019, 0(5): 478-480 |
| |
| 作者姓名： | 邵建芳 董斌 张庆华 |
| |
| 作者单位： | 辽宁省大连市药品不良反应监测中心;辽宁省大连市药品检验所;辽宁省大连医科大学附属第一医院心血管外科 |
| |
| 摘 要： | 血管生成在恶性肿瘤的发生发展以及转移的过程中发挥着重要作用,在肿瘤的分子靶向治疗中抗血管生成已成为重要的治疗手段.目前临床中常用的抗血管生成药物包括单克隆抗体类(代表药物贝伐单抗)、酪氨酸激酶抑制剂类(代表药物索拉菲尼、舒尼替尼)以及内皮细胞生长抑制剂等.不同类别的抗肿瘤血管生成靶向药物其不良反应各不相同,掌握该类药物的不良反应发生机制以及相关不良反应的处理措施,对接受该类药物治疗患者的耐受性会得到提高,同时也使患者预后得到进一步改善.
|
| 关 键 词： | 肿瘤靶向治疗 抗血管生成药物 不良反应 |
Advances in mechanism and management of adverse drug reactions targeting anti-angiogenesis drugs |
| |
| Shao Jianfang,Dong Bin,Zhang Qinghua. Advances in mechanism and management of adverse drug reactions targeting anti-angiogenesis drugs[J]. Clinical Medicine of China, 2019, 0(5): 478-480 |
| |
| Authors: | Shao Jianfang Dong Bin Zhang Qinghua |
| |
| Affiliation: | (Dalian adverse drug reaction monitoring center, Dalian 116021, China;Dalian Institute for drug control, Dalian 116021, China;Department of Cardiovascular Surgery, the First Affiliated Hospital of Dalian Medical University, Dalian 116021, China) |
| |
| Abstract: | Shao Jianfang;Dong Bin;Zhang Qinghua(Dalian adverse drug reaction monitoring center, Dalian 116021, China;Dalian Institute for drug control, Dalian 116021, China;Department of Cardiovascular Surgery, the First Affiliated Hospital of Dalian Medical University, Dalian 116021, China) |
| |
| Keywords: | Targeted therapy of tumor Anti-angiogenie drugs Adverse reactions |
| 本文献已被 维普 等数据库收录！ |
|
